{"id":"W2908942081","doi":"10.2217/imt-2018-0167","title":"Immune Checkpoint Inhibitors and Non-Small-Cell Lung Cancer Management: 2018 Update","year":2019,"lang":"en","type":"editorial","venue":"Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Pembrolizumab; Atezolizumab; Nivolumab; Medicine; Lung cancer; Oncology; Internal medicine; Docetaxel; Avelumab; Ipilimumab; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006821001,0.0009723294,0.001360811,0.0004201459,0.0001947599,0.0001861836,0.0004898316,0.001199065,0.0007070253],"category_scores_gemma":[0.00001222768,0.0008536276,0.0006422207,0.0003760897,0.0002302439,0.0001532724,0.000169874,0.001208272,0.0001162747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006837299,"about_ca_system_score_gemma":0.0005788921,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001571978,"about_ca_topic_score_gemma":0.00003646023,"domain_scores_codex":[0.9960055,0.00007477547,0.001157719,0.001080222,0.0008698046,0.0008119533],"domain_scores_gemma":[0.9974046,0.0001443678,0.000711165,0.001395219,0.000207609,0.0001370472],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.005720158,0.0002536766,0.0002691631,0.002330377,0.003031428,0.0000642323,0.000523633,0.000001322693,0.03329525,0.000004446834,0.929149,0.02535728],"study_design_scores_gemma":[0.01499165,0.0004232154,0.0009466347,0.002189493,0.0005421899,0.000009025604,0.0001006383,0.000044962,0.006820779,0.000009516677,0.9729915,0.0009304444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.02273719,0.1644692,0.00008492187,0.0007851321,0.804007,0.003212612,0.000293508,0.0001949664,0.004215504],"genre_scores_gemma":[0.002502617,0.4100301,0.0007919825,0.001244901,0.5193053,0.0006859327,0.001054227,0.0006822309,0.0637027],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.2847017,"threshold_uncertainty_score":0.9993914,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.005902408804642505,"score_gpt":0.2602707838035951,"score_spread":0.2543683749989526,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}